Clinical Trial Update: DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating DTaP-IPV-HB-PRP-T as a primary series and a second-year booster in HIV-exposed infants (infected and uninfected).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• HIV Infection
• Hepatitis B
• Pertussis
• Polio
• Tetanus

Drugs mentioned

• DTaP-IPV-HB-PRP~T Combined Vaccine

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Diphtheria, Tetanus | Phase 3 | Status: COMPLETED